Edition:
United States

Biocept Inc (BIOC.OQ)

BIOC.OQ on NASDAQ Stock Exchange Capital Market

1.56USD
2:09pm EDT
Change (% chg)

$0.74 (+90.24%)
Prev Close
$0.82
Open
$1.14
Day's High
$1.70
Day's Low
$1.06
Volume
8,085,586
Avg. Vol
395,095
52-wk High
$12.12
52-wk Low
$0.66

Latest Key Developments (Source: Significant Developments)

Biocept Q1 Loss Per Share $0.61
Wednesday, 8 May 2019 04:05pm EDT 

May 8 (Reuters) - Biocept Inc ::BIOCEPT REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.61.Q1 REVENUE $1.0 MILLION.QTRLY REVENUES INCREASED 27% COMPARED TO Q1 OF 2018.NET LOSS FOR Q1 OF 2019 WAS $5.9 MILLION, OR $0.61 PER SHARE.  Full Article

Biocept Inc Files For Offering Of Up To 5.95 Mln Shares Of Co's Common Stock By The Selling Stockholders
Wednesday, 10 Apr 2019 05:22pm EDT 

April 10 (Reuters) - Biocept Inc ::BIOCEPT INC FILES FOR OFFERING OF UP TO 5.95 MILLION SHARES OF CO'S COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING.  Full Article

Biocept Q4 Loss Per Share $1.43
Thursday, 28 Mar 2019 04:05pm EDT 

March 28 (Reuters) - Biocept Inc ::BIOCEPT REPORTS 2018 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS.Q4 LOSS PER SHARE $1.43.Q4 EARNINGS PER SHARE ESTIMATE $-1.41 -- REFINITIV IBES DATA.Q4 REVENUE $860,000 VERSUS REFINITIV IBES ESTIMATE OF $912,000.CASH AND CASH EQUIVALENTS WERE $3.4 MILLION AS OF DECEMBER 31, 2018, COMPARED WITH $2.1 MILLION AS OF DECEMBER 31, 2017.  Full Article

Biocept Announces Pricing Of $7.5 Mln Underwritten Public Offering
Friday, 8 Feb 2019 08:45am EST 

Feb 8 (Reuters) - Biocept Inc ::BIOCEPT ANNOUNCES PRICING OF $7.5 MILLION UNDERWRITTEN PUBLIC OFFERING.BIOCEPT - EACH SHARE OF IS BEING SOLD TOGETHER WITH ONE WARRANT TO PURCHASE ONE SHARE AT A COMBINED PRICE TO PUBLIC OF $1.20 PER SHARE AND WARRANT.BIOCEPT INC - WARRANTS WILL BE IMMEDIATELY EXERCISABLE AT A PRICE OF $1.20 PER SHARE OF COMMON STOCK AND WILL EXPIRE FIVE YEARS FROM DATE OF ISSUANCE.  Full Article

Lincoln Park Capital Fund Llc Reports 9.99 Pct Passive Stake In Biocept Inc As Of September 20
Monday, 24 Sep 2018 05:22pm EDT 

Sept 24 (Reuters) - Biocept Inc ::LINCOLN PARK CAPITAL FUND LLC REPORTS 9.99 PERCENT PASSIVE STAKE IN BIOCEPT INC AS OF SEPTEMBER 20 - SEC FILING.  Full Article

Biocept Enters Into Agreement With Alliance Global FZ
Friday, 13 Jul 2018 08:05am EDT 

July 13 (Reuters) - Biocept Inc ::BIOCEPT ENTERS INTO AGREEMENT WITH ALLIANCE GLOBAL FZ TO MARKET AND DISTRIBUTE LIQUID BIOPSY TESTING IN THE MIDDLE EAST, SOUTHEAST ASIA, AND AFRICA REGION.BIOCEPT INC - ADDITIONAL TERMS OF AGREEMENT WERE NOT DISCLOSED..BIOCEPT - EXPANDS INTERNATIONAL DISTRIBUTION OF TARGET SELECTOR PLATFORM TO 17 COUNTRIES.  Full Article

Biocept Says Pursuant To Approval Of Co's Board, Co Effected A Reverse Stock Split Of Co's Common Stock
Friday, 6 Jul 2018 05:26pm EDT 

July 6 (Reuters) - Biocept Inc ::BIOCEPT SAYS PURSUANT TO APPROVAL OF CO'S BOARD, CO EFFECTED A REVERSE STOCK SPLIT OF CO'S COMMON STOCK AT A RATIO OF 1:30 - SEC FILING.  Full Article

Biocept Inc Files For Mixed Shelf Of Up To $50 Million
Tuesday, 15 May 2018 05:51pm EDT 

May 15 (Reuters) - Biocept Inc ::BIOCEPT INC FILES FOR MIXED SHELF OF UP TO $50 MILLION – SEC FILING.  Full Article

Biocept Prices $15 Million Public Offering Of 33.3 Mln Shares and Warrants
Friday, 26 Jan 2018 06:31am EST 

Jan 26 (Reuters) - Biocept Inc ::BIOCEPT ANNOUNCES PRICING OF $15.0 MILLION PUBLIC OFFERING OF 33,333,333 SHARES OF COMMON STOCK AND WARRANTS TO PURCHASE 33,333,333 SHARES OF COMMON STOCK.BIOCEPT INC - PRICING OF OFFERING OF UP TO 33.3 MILLION SHARES AND WARRANTS TO PURCHASE UP TO 33.3 MILLION SHARES OF COMMON STOCK AT COMBINED PRICE OF $0.45.  Full Article

Biocept Offers 18.8 Mln Shares Of Common Stock
Monday, 22 Jan 2018 05:04pm EST 

Jan 22 (Reuters) - Biocept Inc ::BIOCEPT INC FILES TO SAY IT OFFERING 18.8 MILLION SHARES OF ITS COMMON STOCK AND WARRANTS TO PURCHASE SHARES OF COMMON STOCK - SEC FILING.BIOCEPT INC - OFFERING AT AN ASSUMED COMBINED OFFERING PRICE OF $0.665 PER SHARE OF COMMON STOCK AND ACCOMPANYING WARRANTS.  Full Article

BRIEF-Biocept And Prognos Enter Into Partnership

* BIOCEPT AND PROGNOS ENTER INTO PARTNERSHIP TO APPLY ARTIFICIAL INTELLIGENCE IN ORDER TO HELP PHARMACEUTICAL AND LIFE SCIENCES COMPANIES OPTIMIZE COMMERCIALIZATION OF BIOMARKER-TARGETED THERAPIES IN ONCOLOGY Source text for Eikon: Further company coverage: